Skip to content

Study · Randomized controlled trial · n = 60 · 2002

6 results

Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study.

Ludwig M, Katalinic A, Banz C, Schröder AK, Löning M, Weiss JM, Diedrich K

Human reproduction (Oxford, England)1 Nov 2002Cited by 63 (Europe PMC)

PMID12407036 (opens in a new tab)DOI10.1093/humrep/17.11.2842 (opens in a new tab)PepBankPUB-12407036
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In IVF patients, monitoring visits were similar across the three cetrorelix protocols.

    In plain wordsIn IVF patients, monitoring visits were similar across the three cetrorelix protocols.

    Peptide
    Cetrorelix
    Outcome
    Direction not reportedMonitoring visits
    Study

    n = 60

    Comparator
    Three cetrorelix protocols
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The number of monitoring visits was similar between the three groups.
    3 context sentences
    Summary · context
    The primary endpoints were the number of Cetrotide vials and number of monitoring visits.
    Summary · context
    Sixty patients were prospectively randomized (using sealed envelopes) to receive either the fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1), or an individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2), or an individua…
    Summary · context
    Recombinant human (rh)FSH was used.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In IVF patients, an individualized cetrorelix protocol (start by follicle size, group 2) needed fewer Cetrotide vials than the fixed multiple-dose protocol (4.59 +/- 1.65 versus 6.81 +/- 1.61, P < 0.01).

    In plain wordsIn IVF patients, an individualized cetrorelix start needed fewer vials than the fixed multiple-dose protocol.

    Peptide
    Cetrorelix
    Outcome
    DecreaseCetrotide vials
    Study

    n: not reported in source

    Comparator
    Fixed multiple-dose protocol
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Mean Cetrotide vials
    6.81 vials
    Group 1, fixed multiple-dose protocol, SD 1.61
    Mean Cetrotide vials
    4.59 vials
    Group 2, individualized protocol, SD 1.65

    Source sentences

    Summary
    Patients in group 1 needed significantly more Cetrotide vials (6.81 +/- 1.61) than patients of group 2 (4.59 +/- 1.65; P < 0.01).
    3 context sentences
    Summary · context
    The primary endpoints were the number of Cetrotide vials and number of monitoring visits.
    Summary · context
    Sixty patients were prospectively randomized (using sealed envelopes) to receive either the fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1), or an individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2), or an individua…
    Summary · context
    Recombinant human (rh)FSH was used.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In IVF patients, individualized multiple-dose cetrorelix yielded significantly more retrieved oocytes than the fixed protocol.

    In plain wordsIn IVF patients, individualized multiple-dose cetrorelix yielded significantly more eggs than the fixed protocol.

    Peptide
    Cetrorelix
    Outcome
    IncreaseOocytes retrieved with individualized multiple-dose protocol
    Study

    n: not reported in source

    Comparator
    Fixed multiple-dose protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Surprisingly, the number of retrieved oocytes was significantly higher in the individualized groups as compared with group 1.
    2 context sentences
    Summary · context
    Sixty patients were prospectively randomized (using sealed envelopes) to receive either the fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1), or an individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2), or an individua…
    Summary · context
    Recombinant human (rh)FSH was used.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In IVF patients, individualized single-dose cetrorelix yielded significantly more retrieved oocytes than the fixed protocol.

    In plain wordsIn IVF patients, individualized single-dose cetrorelix yielded significantly more eggs than the fixed protocol.

    Peptide
    Cetrorelix
    Outcome
    IncreaseOocytes retrieved with individualized single-dose protocol
    Study

    n: not reported in source

    Comparator
    Fixed multiple-dose protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Surprisingly, the number of retrieved oocytes was significantly higher in the individualized groups as compared with group 1.
    2 context sentences
    Summary · context
    Sixty patients were prospectively randomized (using sealed envelopes) to receive either the fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1), or an individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2), or an individua…
    Summary · context
    Recombinant human (rh)FSH was used.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In IVF patients, individualized multiple-dose cetrorelix used significantly less total rhFSH than the fixed protocol.

    In plain wordsIn IVF patients, individualized multiple-dose cetrorelix used significantly less total rhFSH than the fixed protocol.

    Peptide
    Cetrorelix
    Outcome
    DecreaseTotal rhFSH use
    Study

    n: not reported in source

    Comparator
    Fixed multiple-dose protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite a significantly lower total amount of rhFSH used, estradiol levels were significantly higher in group 2 as compared with group 1.
    2 context sentences
    Summary · context
    Sixty patients were prospectively randomized (using sealed envelopes) to receive either the fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1), or an individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2), or an individua…
    Summary · context
    Recombinant human (rh)FSH was used.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In IVF patients, individualized multiple-dose cetrorelix produced significantly higher estradiol levels than the fixed protocol.

    In plain wordsIn IVF patients, individualized multiple-dose cetrorelix produced significantly higher estradiol levels than the fixed protocol.

    Peptide
    Cetrorelix
    Outcome
    IncreaseEstradiol levels
    Study

    n: not reported in source

    Comparator
    Fixed multiple-dose protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite a significantly lower total amount of rhFSH used, estradiol levels were significantly higher in group 2 as compared with group 1.
    2 context sentences
    Summary · context
    Sixty patients were prospectively randomized (using sealed envelopes) to receive either the fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1), or an individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2), or an individua…
    Summary · context
    Recombinant human (rh)FSH was used.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.